Spindiag’s fully automated Rhonda PCR system consists of an analyzer, the so-called Rhonda player
with an insertable test cartridge- the Rhonda disk. The innovative platform provides reliable, laboratory-grade PCR test results in well under one hour, making it easy to integrate into everyday clinical practice.
The system was developed for accurate infection control at the point of care, like in the emergency
departments or wards of hospitals with the goal to protect patients and healthcare professionals from
potentially hazardous pathogens.
The test procedure is simple and highly user-friendly: swab samples can be inserted directly into the test cartridge without manual pipetting, saving time and reducing the potential risk of infection for users to a minimum.
Now, The European Investment Bank (EIB) is providing a loan of €15 million for Spindiag GmbH. The newly attained funding will be used for research, scaling-up production, and expansion from Germany into further European markets.
“The EIB supports Spindiag’s research because infectious pathogens in hospitals have become a
challenge that has to be addressed with innovative approaches, such as that of Spindiag. The IDFF
instrument under InnovFin has proven itself useful in medical research.”– says Ambroise Fayolle, EIB’s Vice-President about the funding.
“By simply providing diagnostic results, Spindiag is providing an innovative infection control solution. We are pleased that the EIB has recognized the potential of Rhonda and supports us in addressing the threat of infectious pathogens for healthcare professionals and patients. The EIB capital helps Spindiag in the all-important development of further tests in infection control, ensures expanded production capacities and will help us to implement commercial expansion plans more quickly.”- says Daniel Mark, CEO and Co-founder at Spindiag.
Congratulations on the funding!